Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023

Vitiligo, an autoimmune disorder causing depigmented skin patches, includes two types, segmental (SV) and non-segmental (NSV). Previously, NSV was off-label treated using Calcineurine inhibitors (Tacrolimus and Pimecrolimus). In 2022, the FDA approved Ruxolitinib cream, targeting the JAK/STAT pathwa...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Saleh F. Alqifari, Musaab Habibulla Gari, Jeff J. Guo, Shoroq Alamin, Aya K. Esmail, Abdullah K. Esmail, Heba R. Hamad, Ahmed Aljabri, Amirah M. Alatawi, Laila A. Albishi, Mohammed Olaythah Alraddadi, Helal F. Hetta
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2025-07-01
Serie:	Diseases
Soggetti:	vitiligo adverse events FDA adverse event reporting system (FAERS) calcineurine inhibitors ruxolitinib
Accesso online:	https://www.mdpi.com/2079-9721/13/7/208
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!